LGD-6972 Solution
L6972-03
Phase 1 small_molecule completed
Quick answer
LGD-6972 Solution for Type 2 Diabetes Mellitus (T2DM) is a Phase 1 program (small_molecule) at LIGAND PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- LIGAND PHARMACEUTICALS INC
- Indication
- Type 2 Diabetes Mellitus (T2DM)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed